

Clinical trials of anti hypertensive agent for hypertension in patients with treatment-resistant hypertension

TrialResults-center www.trialresultscenter.org

1 endothelin receptor antagonist

Trial	Treatments	Patients	Trials design and methods
darusentan vs placebo			
DORADO-AC n=NA follow-up:	-	-	
DORADO , 2009 [NCT00330369] n=247/132 follow-up: 14 weeks	darusentan 50 mg, 100 mg or 300 mg versus placebo	patients with treatment-resistant hypertension	Parallel groups double blind North and South America, Europe, New Zealand, Australia

References

DORADO-AC, :
DORADO, 2009:

Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, Linseman JV, Wiens BL, Warren MS, Lindholm LH A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1423-31 [19748665]

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.